[At the crossroads between B lymphoproliferative syndromes to autoimmune diseases are CD5-positive B-lymphocytes: a new hypothesis].
Cells of most of the chronic lymphoid leukemias of the B cell lineage express the CD5 molecule, and this CD5 + B cell subset may be expanded in nonorgan-specific autoimmune diseases. Since autoimmune features are common in lymphoproliferative disorders and the latter be a complication in autoimmune settings, CD5 + B cell may stand at the crossroads of these two conditions. Our hypothesis is, therefore, that there are differences in CD5 + B cells arising during ontogeny ("classical") and those whereby CD5 is induced by various stimuli ("induced"). There is also evidence to support a role for CD5 on B cells, sustaining the proliferation of activated B cells, whereas resting B cells undergo apoptosis.
Youinou
P
P
Laboratoire d'Immunologie, Institut de Synergie des Sciences et de la Santé, Centre Hospitalier Universitaire, Brest.
D001327:Autoimmune Diseases / Q000276:immunology*; D001402:B-Lymphocytes / Q000276:immunology*; D018956:CD5 Antigens / Q000097:blood*; D006801:Humans; D008232:Lymphoproliferative Disorders / Q000276:immunology*
D018956:CD5 Antigens
Au carrefour entre syndromes lympho-prolifératifs B et maladies auto-immunes ... les lymphocytes BCD5 plus: une nouvelle hypothèse.